- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00402831
ProQuad® Intramuscular vs Subcutaneous
August 10, 2018 updated by: Merck Sharp & Dohme LLC
An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad® When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months
Primary objective:
To demonstrate that two doses of ProQuad® administered by IM route are as immunogenic as two doses of ProQuad® administered by SC route to healthy children 12 to 18 months of age in terms of antibody response rates to measles, mumps, rubella and to varicella at 42 days following the second dose of ProQuad®
Secondary objectives:
- To describe the antibody response rates to measles, mumps, rubella and varicella measured 30 days following the first dose of ProQuad® administered by IM or SC route,
- To describe the antibody titres to measles, mumps, rubella and varicella at 30 days following the first dose and at 42 days following the second dose of ProQuad® both administered by IM or SC route,
- To describe the safety profile of two doses of ProQuad® both administered by IM or SC route.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
405
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 1 year (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy participant of either gender,
- Age 12 to 18 months,
- Negative clinical history of measles, mumps, rubella, varicella and zoster,
- Consent form signed by both holders of the parental authority or by the legal representative
- Holder(s) of the the parental authority / legal representative able to understand the protocol requirements and to fill in the Diary Card.
Exclusion Criteria:
- Prior receipt of measles, mumps, rubella and/or varicella vaccine either alone or in any combination,
- Any recent (≤30 days) exposure to measles, mumps, rubella, varicella and/or zoster
- Any recent (≤3 days) history of febrile illness
- Any severe chronic disease,
- Active untreated tuberculosis,
- Known personal history of seizure disorder,
- Any known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems,
- Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,
- Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity including those resulting from corticosteroid [any long-term (≥14 days) administration of systemic corticosteroid therapy given daily or on alternate days at high doses (≥2 mg/kg/day prednisone equivalent or ≥20 mg/day if weight more than 10 kg) within the previous 30 days] or other immunosuppressive therapy,
- Any previous (≤ 150 days) receipt of immune globulin or any blood-derived product or scheduled to be administered through Visit 3,
- Any recent (≤7 days) tuberculin test or scheduled tuberculin test through Visit 3,
- Any recent (≤30 days) receipt of an inactivated or a live vaccine or scheduled vaccination through Visit 3,
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intramuscular ProQuad®
Participants will receive doses of ProQuad® by IM injection on Day 1 and Day 30 into the deltoid muscle perpendicular to the skin, with the first dose in the right arm and the second dose in the left arm.
|
Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.
|
Active Comparator: Subcutaneous ProQuad®
Participants will receive doses of ProQuad® by SC injection on Day 1 and Day 30 in the deltoid area at a 45° angle to the skin, with the first dose in the right arm and second dose in the left arm.
|
Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Meeting Antibody Response Rate Criteria Six Weeks After Completing ProQuad® Treatment
Time Frame: Week 10 (6 weeks after Dose 2 on Week 4)
|
Antibody response rates were determined 6 weeks after the second dose of IM or SC ProQuad®.
Measles, mumps and rubella antibody levels were determined using enzyme-linked immunosorbent assay (ELISA) and varicella antibody levels were determined with glycoprotein-based ELISA (gpELISA).
Response rates were determined as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre <255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre <10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre <10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre <1.25 gpELISA units/mL.
|
Week 10 (6 weeks after Dose 2 on Week 4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Meeting Antibody Response Rate Criteria Four Weeks After the First ProQuad® Dose
Time Frame: Week 4
|
Antibody response rates were determined 4 weeks after the first dose of IM or SC ProQuad®.
Measles, mumps and rubella antibody levels were determined using ELISA and varicella antibody levels were determined with gpELISA.
Response rates were determined as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre <255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre <10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre <10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre <1.25 gpELISA units/mL.
|
Week 4
|
Antibody Geometric Mean Titres (GMT) to Measles Four Weeks After the First ProQuad® Dose
Time Frame: Week 4
|
Antibody titre levels to measles were determined 4 weeks after the first dose of IM or SC ProQuad®.
Measles antibody levels were determined using ELISA.
Titre levels were determined in participants with baseline measles titre <255 mIU/mL.
|
Week 4
|
Antibody GMT to Mumps Four Weeks After the First ProQuad® Dose
Time Frame: Week 4
|
Antibody titre levels to mumps were determined 4 weeks after the first dose of IM or SC ProQuad®.
Mumps antibody levels were determined using ELISA.
Titre levels were determined in participants with baseline mumps titres <10 ELISA Ab units mL.
|
Week 4
|
Antibody GMT to Rubella Four Weeks After the First ProQuad® Dose
Time Frame: Week 4
|
Antibody titre levels to rubella were determined 4 weeks after the first dose of IM or SC ProQuad®.
Rubella antibody levels were determined using ELISA.
Titre levels were determined in participants with baseline rubella titre <10 IU/mL.
|
Week 4
|
Antibody GMT to Varicella Four Weeks After the First ProQuad® Dose
Time Frame: Week 4
|
Antibody titre levels to varicella were determined 4 weeks after the first dose of IM or SC ProQuad®.
Varicella antibody levels were determined with gpELISA.
Titre levels were determined in participants with baseline varicella antibody titre <1.25 gpELISA units/mL.
|
Week 4
|
Antibody GMT to Measles Six Weeks After Completing ProQuad® Treatment
Time Frame: Week 10 (6 weeks after Dose 2 on Week 4)
|
Antibody titre levels to measles were determined 6 weeks after the second dose of IM or SC ProQuad®.
Measles antibody levels were determined using ELISA.
Titre levels were determined in participants with baseline measles titre <255 mIU/mL.
|
Week 10 (6 weeks after Dose 2 on Week 4)
|
Antibody GMT to Mumps Six Weeks After Completing ProQuad® Treatment
Time Frame: Week 10 (6 weeks after Dose 2 on Week 4)
|
Antibody titre levels to mumps were determined 6 weeks after the second dose of IM or SC ProQuad®.
Mumps antibody levels were determined using ELISA.
Titre levels were determined in participants with baseline mumps titre <10 ELISA Ab units mL.
|
Week 10 (6 weeks after Dose 2 on Week 4)
|
Antibody GMT to Rubella Six Weeks After Completing ProQuad® Treatment
Time Frame: Week 10 (6 weeks after Dose 2 on Week 4)
|
Antibody titre levels to rubella were determined 6 weeks after the second dose of IM or SC ProQuad®.
Rubella antibody levels were determined using ELISA.
Titre levels were determined in participants with baseline rubella titre <10 IU/mL.
|
Week 10 (6 weeks after Dose 2 on Week 4)
|
Antibody GMT to Varicella Six Weeks After Completing ProQuad® Treatment
Time Frame: Week 10 (6 weeks after Dose 2 on Week 4)
|
Antibody titre levels to varicella were determined 6 weeks after the second dose of IM or SC ProQuad®.
Varicella antibody levels were determined with gpELISA.
Titre levels were determined in participants with baseline varicella antibody titre <1.25 gpELISA units/mL.
|
Week 10 (6 weeks after Dose 2 on Week 4)
|
Percentage of Participants Experiencing an Injection-site Adverse Event (AE) or Vaccine-related Systemic AE After the First ProQuad® Dose
Time Frame: From Day 0 up to Day 28 (up to 28 days after the first ProQuad® dose)
|
An AE is any untoward medical occurrence in a participant administered an investigational medicinal product (IMP) and which does not necessarily have a causal relationship with the IMP.
Injection-site AEs (e.g., erythema, swelling, pain) and systemic vaccine-related AEs (e.g., pyrexia) were AEs of interest.
|
From Day 0 up to Day 28 (up to 28 days after the first ProQuad® dose)
|
Percentage of Participants Experiencing an Injection-site AE or Vaccine-related Systemic AE After the Second ProQuad® Dose
Time Frame: From Day 30 up to Day 58 (up to 28 days after the second ProQuad® dose)
|
An AE is any untoward medical occurrence in a participant administered an IMP and which does not necessarily have a causal relationship with the IMP.
Injection-site AEs (e.g., erythema, swelling, pain) and systemic vaccine-related AEs (e.g., pyrexia) were AEs of interest.
|
From Day 30 up to Day 58 (up to 28 days after the second ProQuad® dose)
|
Percentage of Participants Discontinuing From Study Therapy Due to an AE After the First ProQuad® Dose
Time Frame: From Day 0 up to Day 28 (up to 28 days after the first ProQuad® dose)
|
An AE is any untoward medical occurrence in a participant administered an IMP and which does not necessarily have a causal relationship with the IMP.
|
From Day 0 up to Day 28 (up to 28 days after the first ProQuad® dose)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Anne FIQUET, MD, SPMSD
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 6, 2006
Primary Completion (Actual)
May 11, 2007
Study Completion (Actual)
May 11, 2007
Study Registration Dates
First Submitted
November 21, 2006
First Submitted That Met QC Criteria
November 21, 2006
First Posted (Estimate)
November 22, 2006
Study Record Updates
Last Update Posted (Actual)
August 13, 2018
Last Update Submitted That Met QC Criteria
August 10, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V221-036
- F05-MMRV-304 (Other Identifier: MCMVaccBV (SPMSD) Protocol Number)
- 2006-001986-40 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://www.merck.com/clinicaltrials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Measles
-
Bandim Health ProjectHeidelberg University; Centre de Recherche en Sante de Nouna, Burkina Faso; Navrongo... and other collaboratorsUnknownMeasles VaccineBurkina Faso
-
Bandim Health ProjectUnknown
-
Postgraduate Institute of Medical Education and...Unknown
-
Bandim Health ProjectHeidelberg University; Centre de Recherche en Sante de Nouna, Burkina Faso; Navrongo... and other collaboratorsUnknown
-
Serum Institute of India Pvt. Ltd.Centers for Disease Control and Prevention; University of Colorado, BoulderCompletedProphylaxis for the Measles InfectionIndia
-
Bandim Health ProjectEnrolling by invitationMortality | Measles Vaccine | Hospital Admission | Non-specific (Heterologous) Effects of VaccinesGuinea-Bissau
-
GlaxoSmithKlineCompletedMeasles; Mumps; Rubella | Measles-Mumps-Rubella VaccineUnited States, Finland, Taiwan, Estonia, Puerto Rico
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Not yet recruiting
Clinical Trials on ProQuad®
-
Merck Sharp & Dohme LLCCompletedMeasles | Rubella | Mumps | Varicella
-
Merck Sharp & Dohme LLCCompletedMeasles | Hepatitis A | Rubella | Mumps | Chickenpox
-
Merck Sharp & Dohme LLCCompletedMeasles | Rubella | Mumps | Varicella
-
Merck Sharp & Dohme LLCCompletedHepatitis B | Measles | Pertussis | Rubella | Mumps | Tetanus | Diphtheria | Varicella | Poliomyelitis | Haemophilus InfectionsGermany, Italy
-
Medical University of South CarolinaCompletedRENAL INSUFFICIENCY, CHRONIC | LIVER FAILURE, ACUTE | HEART DISEASEUnited States
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | VaricellaUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedImmunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy ToddlersMeasles | Rubella | Mumps | Varicella | Meningococcal MeningitisUnited States, Puerto Rico
-
Merck Sharp & Dohme LLCCompletedMeasles | Rubella | Mumps | Varicella
-
GlaxoSmithKlineCompletedMeasles-Mumps-RubellaTaiwan, United States, Korea, Republic of
-
Merck Sharp & Dohme LLCCompleted